Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X6PG
|
|||
| Former ID |
DIB012332
|
|||
| Drug Name |
LY-274614
|
|||
| Synonyms |
LY 235959; 137433-06-8; UNII-AR2BHC0C6P; LY-235959; AR2BHC0C6P; Decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid; 3-Isoquinolinecarboxylic acid, decahydro-6-(phosphonomethyl)-, (3S-(3alpha,4aalpha,6beta,8aalpha))-; LY-274614; C11H20NO5P; LY 274614; 136109-04-1; Tocris-1019; LY274614; LY235959; Biomol-NT_000192; SCHEMBL195083; BPBio1_001216; AC1L302W; CHEMBL1448057; CTK0H8339; MolPort-023-275-977; 3-Isoquinolinecarboxylicacid, decahydro-6-(phosphonomethyl)-, (3S,4aR,6S,8aR)-; ZINC31424744; AKOS024456335; NCGC00024942-02
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Dementia [ICD-11: 6D80-6D86] | Terminated | [1] | |
| Company |
Eli Lilly & Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H20NO5P
|
|||
| Canonical SMILES |
C1CC2CNC(CC2CC1CP(=O)(O)O)C(=O)O
|
|||
| InChI |
1S/C11H20NO5P/c13-11(14)10-4-9-3-7(6-18(15,16)17)1-2-8(9)5-12-10/h7-10,12H,1-6H2,(H,13,14)(H2,15,16,17)/t7-,8-,9+,10-/m0/s1
|
|||
| InChIKey |
STIRHCNEGQQBOY-QEYWKRMJSA-N
|
|||
| CAS Number |
CAS 137433-06-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | N-methyl-D-aspartate receptor (NMDAR) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001393) | |||
| REF 2 | The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 1994 Jan;56(1):69-75. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.